Sangitha Palaniappa focuses primarily on mergers and acquisitions and other complex corporate transactions. Her clients include strategic and financial buyers and sellers in public and private transactions.
Cooley advised Alumis (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing therapies using a precision approach to optimize clinical outcomes and significantly improve the lives of patients with immune-mediated diseases, on its definitive agreement with ACELYRIN to merge in an all-stock transaction.
AGS Announces Definitive Agreement to Be Acquired by Brightstar Capital Partners for $1.1 Billion
May 9, 2024
Cooley advised PlayAGS, a global gaming supplier of high-performing slots, tables and interactive products, on its definitive agreement to be acquired by the affiliates of Brightstar Capital Partners for $1.1 billion.
Cooley advised WSO2, a leading provider of application development and identity and access management software to enterprise companies globally, on its agreement to be acquired by EQT’s BPEA Fund VIII (EQT Private Capital Asia).
Cooley advised Sazerac, one of the world’s largest distilled spirits companies, on its agreement to acquire BuzzBallz, a woman-owned and family-operated distillery, winery and brewery in Texas.
RayzeBio Signs Approximately $4.1 Billion Acquisition Agreement With Bristol Myers Squibb
December 26, 2023
Cooley advised RayzeBio, a clinical-stage radiopharmaceutical therapeutics (RPT) company with an innovation-leading position in actinium-based RPTs and a pipeline of potentially first-in-class and best-in-class drug development programs, on its definitive agreement to be acquired by Bristol Myers Squibb.
